Renaissance Technologies LLC increased its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) by 6.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 433,800 shares of the company’s stock after purchasing an additional 26,900 shares during the period. Renaissance Technologies LLC owned approximately 0.90% of Amphastar Pharmaceuticals worth $12,190,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System acquired a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth approximately $513,000. Great West Life Assurance Co. Can acquired a new position in Amphastar Pharmaceuticals in the 3rd quarter valued at $1,189,000. FinTrust Capital Advisors LLC raised its holdings in Amphastar Pharmaceuticals by 75.0% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 7,000 shares of the company’s stock valued at $196,000 after acquiring an additional 3,000 shares in the last quarter. Rafferty Asset Management LLC acquired a new position in Amphastar Pharmaceuticals in the 2nd quarter valued at $269,000. Finally, Aviva PLC acquired a new position in Amphastar Pharmaceuticals in the 2nd quarter valued at $1,974,000. 61.72% of the stock is owned by institutional investors and hedge funds.
Amphastar Pharmaceuticals Trading Down 2.4 %
Shares of AMPH opened at $36.11 on Friday. Amphastar Pharmaceuticals, Inc. has a 52-week low of $26.76 and a 52-week high of $44.46. The business’s fifty day moving average is $30.57 and its 200-day moving average is $29.73. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.75 and a current ratio of 3.99. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of 20.52 and a beta of 0.73.
Analyst Ratings Changes
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments.
Recommended Stories
- Get a free copy of the StockNews.com research report on Amphastar Pharmaceuticals (AMPH)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating).
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
